Literature DB >> 18664382

ERK1/2 and p38 cooperate to delay progression through G1 by promoting cyclin D1 protein turnover.

Ruth M Densham1, Daniel E Todd, Kathy Balmanno, Simon J Cook.   

Abstract

The conditional kinase DeltaMEKK3:ER allows activation of JNK, p38 and ERK1/2 without overt cellular stress or damage and has proved useful in understanding how these pathways regulate apoptosis and cell cycle progression. We have previously shown that activation of DeltaMEKK3:ER causes a sustained G(1) cell cycle arrest which requires p21(CIP1), with ERK1/2 and p38 cooperating to promote p21(CIP1) expression. In cells lacking p21(CIP1), DeltaMEKK3:ER causes only a transient delay in cell cycle re-entry. We now show that this delay in cell cycle re-entry is due to a reduction in cyclin D1 levels. Activation of DeltaMEKK3:ER promotes the proteasome-dependent turnover of cyclin D1; this requires phosphorylation of threonine 286 (T(286)) and expression of cyclin D1T(286)A rescues the delay in G(1)/S progression. DeltaMEKK3:ER-dependent phosphorylation of T(286) does not appear to be mediated by GSK3beta but requires activation of the ERK1/2 and p38 pathways. ERK1/2 can physically associate with cyclin D1 but activation of ERK1/2 alone is not sufficient for phosphorylation of T(286). Rather, cyclin D1 phosphorylation appears to require coincident activation of ERK1/2 and p38. Thus activation of DeltaMEKK3:ER promotes a sustained G(1) cell cycle arrest by a bipartite mechanism involving the rapid destruction of cyclin D1 and the slower more prolonged expression of p21(CIP1). This has parallels with the bipartite response to ionizing radiation and p53-independent mechanisms of G(1) cell cycle arrest in simple organisms such as yeast.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18664382     DOI: 10.1016/j.cellsig.2008.07.005

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  8 in total

1.  Over-expressed human TREK-1 inhibits CHO cell proliferation via inhibiting PKA and p38 MAPK pathways and subsequently inducing G1 arrest.

Authors:  Man Zhang; Hua-Jing Yin; Wei-Ping Wang; Jiang Li; Xiao-Liang Wang
Journal:  Acta Pharmacol Sin       Date:  2016-07-11       Impact factor: 6.150

2.  A monoclonal antibody (Mc178-Ab) targeted to the ecto-ATP synthase β-subunit-induced cell apoptosis via a mechanism involving the MAPKase and Akt pathways.

Authors:  Wen-Juan Wang; Zhan Ma; Yi-Wen Liu; Yi-Qing He; Ying-Zhi Wang; Cui-Xia Yang; Yan Du; Mu-Qing Zhou; Feng Gao
Journal:  Clin Exp Med       Date:  2011-04-20       Impact factor: 3.984

3.  Cip1 tunes cell cycle arrest duration upon calcineurin activation.

Authors:  Mackenzie J Flynn; Jennifer A Benanti
Journal:  Proc Natl Acad Sci U S A       Date:  2022-06-02       Impact factor: 12.779

Review 4.  The double dealing of cyclin D1.

Authors:  Guergana Tchakarska; Brigitte Sola
Journal:  Cell Cycle       Date:  2019-12-29       Impact factor: 4.534

5.  Lifespan extension in a semelparous chordate occurs via developmental growth arrest just prior to meiotic entry.

Authors:  Gunasekaran Subramaniam; Coen Campsteijn; Eric M Thompson
Journal:  PLoS One       Date:  2014-04-02       Impact factor: 3.240

Review 6.  The p38 pathway, a major pleiotropic cascade that transduces stress and metastatic signals in endothelial cells.

Authors:  Isabelle Corre; François Paris; Jacques Huot
Journal:  Oncotarget       Date:  2017-05-29

7.  SULF2 promotes tumorigenesis and inhibits apoptosis of cervical cancer cells through the ERK/AKT signaling pathway.

Authors:  Tao Jiang; Zhao-Hui Chen; Zhe Chen; Dan Tan
Journal:  Braz J Med Biol Res       Date:  2020-02-07       Impact factor: 2.590

8.  Lack of Matrilin-2 favors liver tumor development via Erk1/2 and GSK-3β pathways in vivo.

Authors:  Alexandra Fullár; Kornélia Baghy; Ferenc Deák; Bálint Péterfia; Yvonne Zsák; Péter Tátrai; Zsuzsa Schaff; József Dudás; Ibolya Kiss; Ilona Kovalszky
Journal:  PLoS One       Date:  2014-04-01       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.